Rodica Van Solingen-Ristea Selected Research

Rilpivirine (TMC-278)

1/2022	Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
12/2021	Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
11/2021	Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
11/2021	Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
9/2021	Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
1/2021	Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rodica Van Solingen-Ristea Research Topics

Disease

6	Infections 12/2021 - 07/2016
1	Inflammation (Inflammations) 01/2022
1	Atherosclerosis 01/2022
1	Injection Site Reaction 11/2021
1	Anemia 07/2016
1	Hepatitis C 07/2016
1	Headache (Headaches) 01/2013

Drug/Important Bio-Agent (IBA)

6	Rilpivirine (TMC-278)IBA 01/2022 - 01/2021
5	cabotegravirIBA 12/2021 - 01/2021
1	rilpivirine drug combination dolutegravirIBA 01/2022
1	fibrin fragment D (D-dimer)IBA 01/2022
1	dolutegravirIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Lipopolysaccharide ReceptorsIBA 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 07/2016
1	Immunosuppressive Agents (Immunosuppressants)IBA 07/2016
1	Tacrolimus (Prograf)FDA LinkGeneric 07/2016
1	telaprevirIBA 07/2016
1	Voriconazole (Vfend)FDA LinkGeneric 01/2013

Therapy/Procedure

2	Therapeutics 09/2021 - 07/2016
1	Injections 11/2021
1	Liver Transplantation 07/2016